# Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus

Study · id `cardio:ct-nct04838392` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04838392](<https://clinicaltrials.gov/study/NCT04838392>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04838392

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT04838392. Allocation not applicable; no masking; primary purpose treatment. Start 2024-12 (anticipated); primary completion 2025-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT04838392, source copy `cardio:ctgov-nct04838392-2024-08-01`, retrieved 2026-10-26)
- Planned start: 2024-12 (anticipated) (ClinicalTrials.gov record NCT04838392, source copy `cardio:ctgov-nct04838392-2024-08-01`, retrieved 2026-10-26)
- Primary completion: 2025-07 (anticipated) (ClinicalTrials.gov record NCT04838392, source copy `cardio:ctgov-nct04838392-2024-08-01`, retrieved 2026-10-26)
- Completion: 2025-11 (anticipated) (ClinicalTrials.gov record NCT04838392, source copy `cardio:ctgov-nct04838392-2024-08-01`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04838392, source copy `cardio:ctgov-nct04838392-2024-08-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04838392-2024-08-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus
- Condition: Diabetes Mellitus
- Condition: Type 1 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Device): RIGHTEST Continuous Glucose Monitoring System
- Lead sponsor: Bionime Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 4718f6b7af6211dbec5b1404b41a56305fa77a2d6583a940e44f9fd351a3b377
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
